Products for Research Use Only

Mitiglinide (calcium hydrate)

CAT: 0804-HY-B0682A-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0682A-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel) . Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].
CAS Number
207844-01-7
Product Name Alternative
KAD-1229; S-21403
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Potassium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/Mitiglinide-calcium-hydrate.html
Purity
99.87
Solubility
DMSO : 25 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(N1C[C@@](CCCC2)([H])[C@@]2([H])C1)C[C@@H](C([O-])=O)CC3=CC=CC=C3.[0.5Ca2+].O
Molecular Formula
C19H24NO3.1/2Ca.H2O
Molecular Weight
352.46
Precautions
H302, H315, H319, H335
References & Citations
[1]Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431 (1) :119-25.|[2]Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29 (5-6) :423-7.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched